Seres Therapeutics (NASDAQ:MCRB) Share Price Crosses Above 50 Day Moving Average - What's Next?

Key Points

• Seres Therapeutics' share price has crossed above its 50-day moving average of $15.73, trading at $17.57, a significant increase from its recent low of $12.23.
• The company reported an EPS of ($2.27), exceeding expectations, as analysts had forecasted a loss of ($2.72) for the quarter.
• Institutional investors hold 59.34% of Seres Therapeutics' stock, with notable increases in stakes from Millennium Management, Vontobel Holding, and Invesco Ltd. in recent quarters.

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $15.73 and traded as high as $18.69. Seres Therapeutics shares last traded at $17.57, with a volume of 306,521 shares.

Seres Therapeutics Trading Down 0.1%

The business's 50 day moving average price is $15.73 and its 200-day moving average price is $12.23. The company has a market cap of $153.74 million, a price-to-earnings ratio of -3.82 and a beta of 0.15.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported ($2.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.72) by $0.45. Equities research analysts forecast that Seres Therapeutics, Inc. will post -0.38 EPS for the current fiscal year.

Institutional Trading of Seres Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of MCRB. Millennium Management LLC raised its stake in Seres Therapeutics by 77.2% in the 4th quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company's stock worth $1,505,000 after purchasing an additional 788,762 shares in the last quarter. Vontobel Holding Ltd. raised its stake in Seres Therapeutics by 15.7% in the 1st quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company's stock worth $760,000 after purchasing an additional 147,671 shares in the last quarter. Marshall Wace LLP acquired a new stake in Seres Therapeutics in the 2nd quarter worth about $1,016,000. Invesco Ltd. raised its stake in Seres Therapeutics by 193.2% in the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock worth $96,000 after purchasing an additional 89,995 shares in the last quarter. Finally, SBI Securities Co. Ltd. raised its stake in Seres Therapeutics by 221.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 48,013 shares in the last quarter. Institutional investors and hedge funds own 59.34% of the company's stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.